Posted by Michael Wonder on 16 Apr 2021
FDA approves nivolumab in combination with chemotherapy for metastatic gastric cancer and oesophageal adenocarcinoma
16 April 2021 - Today, the FDA approved nivolumab (Opdivo, Bristol-Myers Squibb) in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and oesophageal adenocarcinoma.
Efficacy was evaluated in CHECKMATE-649, a randomised, multi-center, open-label trial that enrolled 1,581 patients with previously untreated advanced or metastatic gastric cancer, gastro-esophageal junction cancer, or oesophageal adenocarcinoma.
